ACE-031 is a recombinant fusion protein engineered to function as a soluble decoy receptor for myostatin (GDF-8) and related members of the TGF-β superfamily. It plays a critical role in preclinical studies focused on skeletal muscle regulation, musculoskeletal disorders, and protein-ligand interaction dynamics.

Structurally, ACE-031 consists of the extracellular domain of the human activin receptor type IIB (ActRIIB) fused to the Fc portion of human IgG1. This chimeric design enables high-affinity binding to circulating myostatin, activin A, and other inhibitory ligands, thereby preventing their interaction with endogenous cell-surface ActRIIB receptors. As a result, ACE-031 effectively blocks downstream SMAD2/3 signaling in vitro, allowing researchers to examine the physiological consequences of inhibited TGF-β signaling on muscle tissue, bone density, and systemic metabolic function. Its use is particularly prevalent in studies involving sarcopenia, muscular dystrophy models, and cachexia, where enhanced anabolic signaling is desired for analytical comparison.

ACE-031 is supplied as a high-purity lyophilized powder (≥98%, SDS-PAGE and HPLC verified) suitable for use in protein-binding assays, cell culture models, and receptor-ligand mapping. Due to its proteinaceous nature and sensitivity to degradation, proper storage and handling are critical to maintain biological activity and reproducibility across experimental batches.

Format: Lyophilized powder
Purity: ≥98% (SDS-PAGE and HPLC Verified)
Molecular Formula: Recombinant fusion protein (sequence and mass available upon request)
Storage Recommendations: Store at -80°C; reconstituted aliquots should be frozen and protected from repeated freeze-thaw cycles
Intended Research Use: Myostatin inhibition studies, muscle growth signaling, TGF-β receptor blockade, protein-ligand interaction assays
For Research Use Only. Not for human consumption.